Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study

Affiliations

• ¹ Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
• ² Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
• ³ Queen Elizaberth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada.
• ⁴ Leukemia/BMT Program of British Columbia, Vancouver General Hospital, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada.
• ⁵ Department of Hematology, Catholic BMT Center, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
• ⁶ Departments of Medicine and Oncology, Foothills Hospital and Tom Baker Cancer Centre, Calgary, AB, Canada.
• ⁷ Department of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
• ⁸ Department of Haematology-Oncology, Stem Cell Transplant Program, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada.
• ⁹ The Ottawa Hospital Blood & Marrow Transplant Program, Ottawa, ON, Canada.
• ¹⁰ Section of Hematology and Coagulation, Sahlgrenska University Hospital, Sahlgrenska Academy, Göteborg, Sweden.
• ¹¹ Section of Haematology/Oncology, Department of Internal Medicine, Faculty of Medicine, University of Manitoba, CancerCare Manitoba, Winnipeg, MB, Canada.
• ¹² Division of Hematology, McGill University Health Centre, Montreal, QC, Canada.
• ¹³ Department of Hematology, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada.